EyePoint Pharmaceuticals and Ocumension Therapeutics have signed an exclusive license agreement for the development and commercialization of Dexycu in mainland China, Hong Kong, Macau and Taiwan, according to a press release.
Dexycu (dexamethasone intraocular suspension 9%) is used to treat postoperative inflammation after ocular surgery. EyePoint will receive an upfront payment of $2 million and royalties on Dexycu sales, with future milestone payments possibly totaling up to $12 million, while Ocumension will receive the right to develop and commercialize Dexycu in these areas.
“Dexycu
Uncategorized